Garetosmab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | Activin A |
| Clinical data | |
| Other names | REGN-2477 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Garetosmab is a fully human, experimental monoclonal antibody against activin-A. It has been tried in patients with fibrodysplasia ossificans progressiva and the manufacturer, Regeneron, also plans to test it in patients with obesity as an add-on to existing weight loss drugs such as GLP-1 agonists, in order to help patients maintain muscle mass during weight loss.